Laidlaw Downgrades Mast Therapeutics (MSTX) to Neutral
- Wall Street rallies as OPEC reaches output deal
- Pier 1 Imports (PIR) Reports In-Line Q2 EPS; Comps Fall 4.3%
- Intra-Cellular Therapies (ITCI) Announces ITI-007 Phase 3 Missed Primary Endpoint in Schizophrenia
- Vertex Pharma (VRTX) Announces FDA Approval for ORKAMBI in Children 6-11; Lowers 2016 ORKAMBI Revenue Outlook
- After-Hours Stock Movers 09/28: (AEGR) (PIR) (GSAT) Higher; (ITCI) (ATNM) (PRGS) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Laidlaw downgraded Mast Therapeutics (NYSE: MSTX) from Buy to Neutral.
Shares of Mast Therapeutics closed at $0.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cowen Downgrades Mast Therapeutics (MSTX) to Market Perform
- Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell
- Wedbush Cuts Alphabet (GOOGL) to Underperform on Concerns About 'Four Horsemen' of Search Apocalypse
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!